Targeting Replication Stress in Glioblastoma: From Genotoxic Treatment and Inhibitors of the DNA Damage Response to Immunotherapy

Clicks: 1
ID: 320377
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #104 of 105 articles by views in Neuro-Oncology Advances

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Replication stress (RS) encompasses states of impaired DNA replication progression associated with fork slowing, stalling or collapse. RS triggers a specialized branch of the DNA damage response (DDR) called the RS response (RSR) and constitutes a major source of genomic instability, which is a key hallmark of cancer. Cancer cells face high basal levels of RS due to sustained proliferative signaling. Besides endogenous stimuli, RS can be induced by exogenous sources such as chemotherapeutic drugs. In glioblastoma (GBM), the most aggressive primary brain tumor, chronic RS leading to DDR activation is thought to drive enhanced DNA repair and treatment resistance. While chromosomal instability associated with DDR defects drives tumorigenesis, the need to preserve genomic stability to maintain fitness fosters addiction to redundant pathways promoting fork integrity. Targeting these pathways is a promising anti-cancer strategy currently undergoing clinical evaluation. In this review, we provide a molecular overview of RS and the RSR. We also explore the sources of RS in gliomas, along with the biological processes and tumor-specific features that influence the RSR in GBM cells. We then delve into the strategies developed to exploit RS, including strategies harnessing the DDR to foster antitumor immunity.
Reference Key
openalex_W7167793669 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Alexandros Pailas, Ana Catarina Vales de Almeida, Miriam Torres-Fernández, Prof Anthony Chalmers, M. Mittelbronn, Eric Van Dyck
Journal Neuro-Oncology Advances
Year 2026
DOI
10.1093/noajnl/vdag177
URL
https://doi.org/10.1093/noajnl/vdag177
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.